In Vivo is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Following Compass' Lead

Executive Summary

Corporate venture investment programs like Guidant's Compass walk a thin line between traditional business development and traditional venture capital investing. Compass' goal is to help Guidant find new technology early that could eventually help one of Guidant's core business groups but still earn a return on investment in the event the technology ultimately proves of no value to the corporation.

You may also be interested in...



Corporate Venture Capital's Complex Agenda

Several forces--rapid technological obsolescence, the impact of information technology on health care, merger integrations, and the need for double digit revenue growth--have caused increasing numbers of large pharmaceutical and medical device companies to create new corporate venture capital groups. But compared to traditional VC firms, whose only goal is to make money for limited partners, corporate VCs have a heavy agenda. They must choose portfolio companies while balancing often-competing goals of strategic benefit and financial return.

Over The Counter 8 Aug 2022: The ‘Dos and Don’ts’ Of EU Supplement Innovation, With Mihai Inceu

In this episode, HBW Insight talks to regulatory expert Mihai Inceu about the challenges of innovating in Europe’s thriving food supplements market. Senior regulatory affairs officer at consultancy firm Jensen R+, Inceu highlights some of the issues companies face in putting new wellness products onto the European market, particularly if they want to make health claims for herbal ingredients, also known as botanicals. As well as giving good advice about how to avoid getting into trouble with regulators, Inceu also points to some of the latest trends in this dynamic consumer health space.

Medtech Multinationals Up Pace Of Localization Strategies In China

China-specific go-to-market strategies are helping global medtechs access the fast-growing medical device market in China, where localization has become the buzzword for foreign players, writes news and analysis portal Omdia.

Topics

Related Companies

Related Deals

Latest News
See All
UsernamePublicRestriction

Register

IV000960

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel